

Atherosclerotic Cardiovascular Disease A CALL TO ACTION

Atherosclerotic cardiovascular disease affects an estimated 10%–15% of adults over age 21.¹ Although overall mortality due to ASCVD has declined over the last few decades,² it is still the leading cause of morbidity and mortality in the US.³ Statins are important tools to prevent and treat cardiovascular disease,⁴ but in addition to medication, encouraging patients to adopt certain lifestyle habits can reduce the risk of ASCVD. Maintaining an exercise regimen of around 150 minutes per week of moderate physical activity, or 75 minutes of vigorous physical activity, is recommended, along with a healthy diet (vegetables, fruits, nuts, whole grains, vegetable or animal protein) and fewer processed meats, fried foods and refined carbohydrates.⁵

Only about half the patients who could benefit from cholesterol-lowering medicine are taking them, which has highlighted health disparities...

- ▶ Despite an overall decrease in mortality, certain subpopulations (e.g., Hispanics) have seen an increase.⁶
- ▶ African Americans are less likely to receive a statin prescription than their White counterparts.⁷
- ▶ People who are South Asian have a higher risk of ASCVD than some groups.⁸



PREVENTION AND SCREENING ARE KEY

ASCVD is often asymptomatic, highlighting the importance of screening and risk assessment. Certain conditions and factors, including dyslipidemia, diabetes, hypertension and smoking, can increase the risk of developing cardiovascular disease. In addition to emphasizing a healthy lifestyle, the American College of Cardiology and the American Heart Association recommend the following for ASCVD prevention.⁹

AGES 20-39: Assess for risk factors every 4–6 years AGES 40-75: Routinely assess for risk factors and calculate 10-year risk

Screening Tool

+ -× =

Click the icon to calculate your patient's 10-year ASCVD risk

| <5% | LOW RISK | Emphasize healthy lifestyle changes | Eat less red meat/fried foods and more fruits/vegetables Be more physically active Smoke less or not at all Avoid or limit alcohol and caffeine Manage stress |
|-------------------------|----------------------|---|--|
| 5% - <7.5% | BORDERLINE RISK | Emphasize healthy lifestyle changes | |
| ≥ 7.5% - <20% | INTERMEDIATE RISK | Evaluate risk-enhancing factors and consider statin therapy based on results Consider a CAC test to help reclassify risk for preventive interventions* | Refer to the risk factor table below |
| ≥ 20% | HIGH RISK | Immediate statin therapy is recommended | High-intensity dosage (LDL-C Reduction ≥50%) recommended High-intensity statins reduce ASCVD risk 30% more than moderate-intensity statins Closely monitor side effects, increase/ decrease dosage as needed |

| Clinical Risk-Enhancing Factors to Assess | Parameters | |
|--|---|--|
| Family history of premature ASCVD | Males <55 years; Females <65 years | |
| Primary Hypercholesterolemia | LDL-C, 160-189 mg/dL [4.1- 4.8 mmol/L]; non-HDL-C 190-219 mg/dL [4.9-5.6 mmol/L] | |
| Metabolic Syndrome | Increased waist circumference, elevated triglycerides [>175 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 in women mg/dL] are factors; tally of 3 makes the diagnosis | |
| Chronic Inflammatory Conditions | Such as psoriasis, RA or HIV/AIDS | |
| Chronic Kidney Disease | eGFR 15-59 mL/min/1.73 m2 with or without albuminuria, not treated with dialysis or kidney transplantation | |
| Sex Specific Characteristics | History of premature menopause (before age 40) History of pregnancy-associated conditions that increase later ASCVD risk (pre-eclampsia) | |

TALKING TO YOUR PATIENTS ABOUT...

(click to learn more)



MEDICAL CARE AND TREATMENT

- <u>Only 29% of people describe side-effects when taking statins</u>, commonly muscle aches or weakness. These can be easily managed by altering dosage levels or the type of drug prescribed.¹⁰
- About half of patients discontinue statin therapy within the first year, according to multiple studies.¹¹
 - o Data show a much higher risk of stroke, heart attack and even death within 4 years after stopping a statin.¹²
 - o Discuss the specifics of statins with patients. Emphasize how the medication works "silently" to remove bad cholesterol from the blood.
- Encourage patients to "know their numbers" and make sure they are in the LDL Safe Zone.
 - o 70% of high-risk patients never reach the LDL Safe Zone, according to the Family Heart Foundation.¹³
 - o Refer to this **infographic** for cholesterol level zones.¹⁴
- A few tips to increase medication adherence:
 - o Aim for once-daily dosing.
 - o Use automated reminders.
 - o Educate patients on the importance of taking medication on schedule.

• Related topics to discuss with patients:

- o New or worsening symptoms.
- o Medication issues or side effects, such as muscle aches, headaches, dizziness, issues with sleep, etc.
- o Risks of discontinuing medication.
- o Impact of medication without feeling effects.
- o Challenges to managing condition.
- o Advice or support with lifestyle changes.
- o Changes in appetite or weight.

EMOTIONAL AND MENTAL HEALTH

- <u>Studies</u> show that psychological stress is associated with increased triglycerides, increased LDL and decreased HDL.¹⁵
- Education on mindfulness-based interventions and referral to stress management programs can help <u>address patient</u> <u>stress</u> and improve CVD outcomes.¹⁶ Read more about mindfulness-based interventions here:
 - <u>Meditation and Mindfulness: What You Need To Know | NCCIH (nih.gov)</u>
- Related topics to discuss with patients:
 - o Sharing goals and realistic expectations.
 - o Coping with heart disease and other conditions.
 - o Feeling unusually sad or anxious.
 - o Sources of stress.
 - o Not getting enough sleep or sleeping too much.
 - o Benefits of seeing a therapist or joining a support group.

PHYSICAL HEALTH AND FITNESS

- Brief counseling integrating cognitive behavioral strategies, such as assessment of self-efficacy, goal-setting, and self-monitoring is <u>associated</u> with improvements in cardiorespiratory fitness.¹⁷ Read more about evidence based recommendations for promoting physical activity here: <u>Interventions to Promote Physical Activity and Dietary Lifestyle</u> <u>Changes for Cardiovascular Risk Factor Reduction in Adults | Circulation (ahajournals.org)</u>
- The five A's model can help physicians structure brief and individually tailored counseling on physical activity:
 - o Assess the patient's current level of physical activity.
 - Advise patients with structured recommendations
 (i.e., engage in 30 minutes of moderate-/high-intensity physical activity 5+ days a week).
 - o *Agree* with patients on a plan, through shared decision making and based on their state of change (precontemplation, contemplation, preparation, action/maintenance).
 - o Assist patients by equipping them with resources or self-monitoring tools.
 - o Arrange follow-up by scheduling a visit or a referral to additional counseling or intervention.
- Related topics to discuss with patients:
 - o Difficulty doing daily tasks or chores.
 - o Ability to work or care for family.
 - o Activity level (documented in a physical activity vital sign).18
 - o Trouble standing up, recent falls or balance issues.

Read more about the five A's and counseling recommendations here: Physical Activity Counseling | AAFP

Risk Factor Table - Source: Wong, 2022, ACC/AHA, 2019, Maganti, 2019, Mayo Clinic 2021

REFERENCES

- 1 Gu, J., Sanchez, R., Chauhan, A., Fazio, S., & Wong, N. (2022). Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update. American Journal of Preventive Cardiology, 10, 100336. https://doi. org/10.1016/j.ajpc.2022.100336
- 2 Wall, H. K., Ritchey, M. D., Gillespie, C., Omura, J. D., Jamal, A., & George, M. G. (2018). Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 — United States, 2011–2016. MMWR. Morbidity and Mortality Weekly Report, 67(35), 983– 991. https://doi.org/10.15585/mmwr.mm6735a4
- 3 Al Rifai, M., Blumenthal, R. S., Stone, N. J., Schofield, R. S., Orringer, C. E., Michos, E. D., Heidenreich, P. A., Braun, L., Birtcher, K. K., Smith, S. C., Nambi, V., Grundy, S., & Virani, S. S. (2021). Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Progress in Cardiovascular Diseases, 68, 2–6. https://doi.org/10.1016/j.pcad.2021.08.001
- 4 CDC. (2023, May 15). High Cholesterol Facts | cdc.gov. Centers for Disease Control and Prevention. https://www.cdc.gov/cholesterol/facts.htm
- 5 Lifestyle Changes for Heart Failure. (n.d.). Www.Heart.Org. Retrieved October 4, 2023, from https://www.heart.org/en/health-topics/heart-failure/treatment-options-for-heart-failure/lifestyle-changes-for-heart-failure
- 6 Wall, H. K., Ritchey, M. D., Gillespie, C., Omura, J. D., Jamal, A., & George, M. G. (2018). Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 — United States, 2011–2016. MMWR. Morbidity and Mortality Weekly Report, 67(35), 983– 991. https://doi.org/10.15585/mmwr.mm6735a4
- 7 Khatib, R., Glowacki, N., Lauffenburger, J., Siddiqi, A. (2021). Race/Ethnic Differences in Atherosclerotic Cardiovascular Disease Risk Factors Among Patients With Hypertension: Analysis From 143 Primary Care Clinics, American Journal of Hypertension, Volume 34, Issue 9, Pages 948–955, https://doi.org/10.1093/ajh/hpab053
- 8 American Heart Association (2020). My Cholesterol Guide: Take Action. Live Healthy! https://professional.heart.org/-/media/Files/Health-Topics/Cholesterol/My-Cholesterol-Guide-English.pdf
- 9 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines | (2019) Vol 140:e596–e646 https://doi.org/10.1161/ CIR.00000000000678
- 10 Million Hearts, Department of Health and Human Services. (2018). The Scoop on Statins: What Do You Need to Know? https://millionhearts. hhs.gov/files/Scoop_on_Statins-508.pdf
- 11 Maningat, P., Gordon, B.R., Breslow, J.L. (2013) How do we improve patient compliance and adherence to long-term statin therapy? Current Atherosclerosis Reports. Jan;15(1):291. doi: 10.1007/s11883-012-0291-7. PMID: 23225173; PMCID: PMC3534845.
- 12 Zhang, H., Plutzky, J., Shubina, M., & Turchin, A. (2017). Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes. Annals of Internal Medicine, 167(4), 221–227. https://doi.org/10.7326/M16-0838
- 13 LDL Safe Zone. (2023). Family Heart Foundation. Retrieved October 4, 2023, from https://familyheart.org/ldlsafezone
- 14 Cholesterol: Understanding Levels and Numbers. (2022). Cleveland Clinic. Retrieved October 4, 2023, from https://my.clevelandclinic.org/ health/articles/11920-cholesterol-numbers-what-do-they-mean
- 15 Assadi, S. N. (2017). What are the effects of psychological stress and physical work on blood lipid profiles? Medicine, 96(18), e6816. https://doi.org/10.1097/MD.00000000006816
- 16 Scott-Sheldon, L. A. J., Gathright, E. C., Donahue, M. L., Balletto, B., Feulner, M. M., DeCosta, J., Cruess, D. G., Wing, R. R., Carey, M. P., & Salmoirago-Blotcher, E. (2020). Mindfulness-Based Interventions for Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis. Annals of Behavioral Medicine, 54(1), 67–73. https://doi.org/10.1093/abm/kaz020
- 17 Simons-Morton, D. G., Blair, S. N., King, A. C., Morgan, T. M., Applegate, W. B., O'Toole, M., Haskell, W. L., Albright, C. L., Cohen, S. J., Ribisl, P. M., & Shih, J. H. (2001). Effects of physical activity counseling in primary care: The Activity Counseling Trial: A randomized controlled trial. JAMA: Journal of the American Medical Association, 286(6), 677–687. https://doi.org/10.1001/jama.286.6.677
- 18 Golightly, Y. M., Allen, K. D., Ambrose, K. R., Stiller, J. L., Evenson, K. R., Voisin, C., Hootman, J. M., & Callahan, L. F. (2017). Physical Activity as a Vital Sign: A Systematic Review. Preventing Chronic Disease, 14, E123. https://doi.org/10.5888/pcd14.170030

